A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

NCT02963766 on ClinicalTrials.gov · last registry update 2022-07-01

A small phase 3 — 154 participants, against a typical 424. The sponsor logged completion for 12 June 2021. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 154
Started: 2016-12-29
Primary completion: 2021-06-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.